CelcuityCELC
About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Employees: 55
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
159% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 17
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
14% more funds holding
Funds holding: 92 [Q2] → 105 (+13) [Q3]
10.65% less ownership
Funds ownership: 91.73% [Q2] → 81.08% (-10.65%) [Q3]
15% less capital invested
Capital invested by funds: $530M [Q2] → $450M (-$80M) [Q3]
78% less call options, than puts
Call options by funds: $504K | Put options by funds: $2.27M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 28% 1-year accuracy 41 / 147 met price target | 117%upside $27 | Buy Reiterated | 15 Nov 2024 |
Needham Gil Blum 28% 1-year accuracy 40 / 142 met price target | 84%upside $23 | Buy Reiterated | 15 Nov 2024 |
Stifel Bradley Canino 19% 1-year accuracy 4 / 21 met price target | 237%upside $42 | Buy Maintained | 7 Oct 2024 |
LifeSci Capital Oliver McCammon 0 / 0 met price target | 117%upside $27 | Outperform Initiated | 26 Aug 2024 |
Financial journalist opinion
Based on 4 articles about CELC published over the past 30 days
